🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

TRAP trial: SBRT en px con oligoprogresion resistente a la castracion. ✔️Fase II ✔️En tto con Abi o Enza ✔️ < 2 lesiones. ✔️ PFS: 6.4 m (95% CI, 5.9-11.4 redjournal.org/article/S0360-…

Some prostate patients experience urinary urgency during their radiation treatment. ​ That pressure can cause the prostate to move inferiorly, highlighted here in the video below courtesy of Dr Cem Onal, University of Başkent John Christodouleas #ProgressThroughCollaboration

More fodder for the bladder filling debate. Vedang Murthy Priyamvada Maitre

Data to support why the PTV matters in primary RCC SBRT from our Aussie friends. “Sparing functional kidney from high-dose regions (>50% isodoses) may help reduce risk of functional loss.” pubmed.ncbi.nlm.nih.gov/26873790/ MR-Linac Consortium Shankar Siva

Radiotherapy can be an impactful tool in oligometastatic disease, improving local control while micrometastases are managed with systemic therapy. Does it improve survival? Let's find out!

Great collaboration between MOMENTUM and Oligocare registries, presenting the preliminary outcomes (of 15 institutions) regarding liver SBRT using MRI or CT guided approach during #ESTRO2025 !

297 liver oligo met patients accrued from 2019-2023, with 2yr LC and OS outcome estimates reported in May of 2025! And BTW, within MOMENTUM, the accrual of this subgroup has doubled since 2023. This is the power of platform registries for emerging technologies and treatments.

Stefano Arcangeli Neil Desai Thanks for listening to talk - few highlight slides here. Credit goes to great collaborators across trial group @ UMichigan, UPenn, Cleveland Clinic, U Colorado, Stony Brook, UCSF and UTSW

Proud of the achievements of our team in radiotherapy innovation for cancer care, confirmed also ESTRO #ESTRO2025 . special thanks Elekta to support us on MRlinac research 💪

📣 Registration & housing for #ASTRO25 are NOW OPEN! This year's Annual Meeting will take place September 27 ‒ October 1 in San Francisco, CA. ➡️ Learn more & register here: ow.ly/FSUg50VRhe3

🤞2nd patient soon! ULTRAS is a Ph3 RCT (PI Ali Hosni) of 2 dose levels for 1 fx MR-guided SBRT for liver mets. A hesitation w 1 fx CT-based RT was risk of marginal miss. W better visualization & on table adaptation, I think MR-guided RT has great potential in this setting.

We asked the study team to explain NRG-CC014, the PREEMPT Study, which recently activated & is now enrolling patients with high-risk bone asymptomatic metastases. ow.ly/TngB50VSJnK Sign up for the webinar to learn more about this trial. ⬇️ Erin Gillespie, MD MPH

👇One step closer to Fiducial-free, Sim-free, Single fraction SABR to liver mets. That's where the MR-Linac Consortium is pushing and it will be a blessing for patients. Especially in regions where IR docs are few... and maybe even where they are plentiful🙂 Ali Hosni Todd Aguilera MD PhD

🚨 Randomized Trial: Significantly less symptom burden with SRS compared to HA-WBRT. SRS Standard of Care for 5-20 brain mets 🚨🚨🚨